abrdn Healthcare Investors (NYSE:HQH) Reaches New 52-Week High – Time to Buy?

abrdn Healthcare Investors (NYSE:HQH)’s stock price hit a new 52-week high on Monday . The stock traded as high as $22.31 and last traded at $22.1560, with a volume of 194715 shares. The stock had previously closed at $21.84.

abrdn Healthcare Investors Price Performance

The stock’s 50-day moving average is $20.76 and its 200 day moving average is $19.71.

abrdn Healthcare Investors Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Thursday, May 21st were given a $0.61 dividend. The ex-dividend date of this dividend was Thursday, May 21st. This represents a $2.44 dividend on an annualized basis and a dividend yield of 10.8%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Bollard Group LLC purchased a new stake in abrdn Healthcare Investors in the first quarter valued at approximately $25,000. Geneos Wealth Management Inc. increased its holdings in shares of abrdn Healthcare Investors by 9,232.3% in the 2nd quarter. Geneos Wealth Management Inc. now owns 2,893 shares of the financial services provider’s stock valued at $45,000 after acquiring an additional 2,862 shares during the period. Flagship Harbor Advisors LLC acquired a new position in shares of abrdn Healthcare Investors in the 4th quarter valued at $48,000. Advisory Services Network LLC purchased a new stake in abrdn Healthcare Investors in the 3rd quarter valued at $97,000. Finally, Global Retirement Partners LLC purchased a new stake in abrdn Healthcare Investors in the 4th quarter valued at $106,000. Institutional investors and hedge funds own 32.60% of the company’s stock.

About abrdn Healthcare Investors

abrdn Healthcare Investors (NYSE:HQH) is a closed-end management investment company that seeks long-term capital appreciation and current income by investing primarily in equity securities of companies operating in the healthcare sector. The fund’s portfolio generally comprises a diversified mix of domestic and international healthcare issuers, spanning pharmaceuticals, biotechnology, medical devices, healthcare services, and related industries.

The fund employs a fundamental, research-driven approach to select investments, focusing on companies with strong balance sheets, innovative product pipelines and the potential for sustainable revenue growth.